Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday

Dogwood Therapeutics (NASDAQ:DWTX) is projected to issue its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 23, 2026 at 8:00 AM ET.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.96. On average, analysts expect Dogwood Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Dogwood Therapeutics Price Performance

Dogwood Therapeutics stock opened at $3.00 on Monday. Dogwood Therapeutics has a 12 month low of $2.60 and a 12 month high of $9.50. The company has a fifty day moving average price of $2.95 and a two-hundred day moving average price of $4.66. The company has a market cap of $100.21 million, a PE ratio of -0.16 and a beta of 1.90.

Wall Street Analysts Forecast Growth

DWTX has been the topic of a number of recent research reports. Wall Street Zen downgraded shares of Dogwood Therapeutics to a “strong sell” rating in a research report on Saturday, December 13th. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Dogwood Therapeutics in a research note on Friday, February 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Dogwood Therapeutics has a consensus rating of “Hold” and a consensus price target of $12.00.

Institutional Investors Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 9.05% of the stock is owned by institutional investors.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.